GALERA THERAPEUTICS
Galera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation therapy is used in patients with cancer. Galera’s lead product candidate is GC4419, a highly selective and potent small molecule superoxide dismutase enzyme mimetic that rapidly converts superoxide to hydrogen peroxide and oxygen. GC4419 achieved positive results in a Phase ... 2b clinical trial, which demonstrated its ability to reduce the incidence and duration of radiation-induced severe oral mucositis in patients with head and neck cancer, it's lead indication. The U.S. Food and Drug Administration granted Fast Track and Breakthrough Therapy designations to GC4419. The company was established in 2009 and is headquartered in Malvern, Pennsylvania, United States.
GALERA THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2009-01-01
Address:
Malvern, Pennsylvania, United States
Country:
United States
Website Url:
http://www.galeratx.com
Total Employee:
11+
Status:
Active
Contact:
610-725-1500
Total Funding:
148.61 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Venture Round - Galera Therapeutics
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - Galera Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series C - Galera Therapeutics
Rock Springs Capital
Rock Springs Capital investment in Series C - Galera Therapeutics
Adage Capital Management
Adage Capital Management investment in Series C - Galera Therapeutics
Tekla Capital Management
Tekla Capital Management investment in Series C - Galera Therapeutics
Correlation Ventures
Correlation Ventures investment in Series C - Galera Therapeutics
Novartis Venture Fund
Novartis Venture Fund investment in Series C - Galera Therapeutics
Novo Ventures
Novo Ventures investment in Series C - Galera Therapeutics
Clarus Ventures
Clarus Ventures investment in Series C - Galera Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-12 | Galera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance Officer |
Official Site Inspections
http://www.galeratx.com Semrush global rank: 5.02 M Semrush visits lastest month: 1.66 K
- Host name: 196.217.174.34.bc.googleusercontent.com
- IP address: 34.174.217.196
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Galera Therapeutics"
About Galera - Galera Therapeutics, Inc.
Galera was founded in 2012 with the mission to develop and commercialize novel therapeutics that have the potential to transform radiotherapy in cancer. With patients as the driving force, we are pioneering a novel scientific approach to …See details»
Corporate Profile - Galera Therapeutics, Inc.
Jun 27, 2023 Galera Therapeutics is aiming to transform radiotherapy for patients with cancer by developing novel therapies to reduce radiotherapy-induced toxicities and improve the anti-cancer efficacy of radiation. NASDAQ: …See details»
Galera Therapeutics, Inc. - Investors
May 13, 2024 The Investor Relations website contains information about Galera Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Galera Therapeutics Company Description - Stock Analysis
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer.See details»
Galera Therapeutics, Inc. (GRTX) - Yahoo Finance
See the company profile for Galera Therapeutics, Inc. (GRTX) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Galera Therapeutics - Crunchbase Company Profile
Galera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation …See details»
Galera Therapeutics - PitchBook
Galera Therapeutics General Information Description. Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform …See details»
SEC Filings - Galera Therapeutics, Inc.
Nov 15, 2024 Aug 16, 2024: Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing. 144See details»
Galera Therapeutics, Inc. - SEC Filing
Nov 14, 2023 45 Liberty Blvd #230. Malvern, PA 19355 (Address of principal executive offices) (Zip Code) (610) 725-1500 (Registrant’s telephone number, include area code) N/A (Former …See details»
Galera Therapeutics - Overview, News & Similar companies
May 13, 2024 Galera Therapeutics contact info: Phone number: (610) 725-1500 Website: www.galeratx.com What does Galera Therapeutics do? Galera Therapeutics, Inc. is a clinical …See details»
Galera Therapeutics Inc, GRTX:PKL profile - FT.com - Financial Times
Nov 27, 2024 Galera Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of novel, therapeutic candidates that have the potential to transform radiotherapy in …See details»
Company Information - RocketReach
Galera Therapeutics, Inc. employs 31 employees. The Galera Therapeutics, Inc. management team includes Sorensen Mel (President and CEO), Colleen Hamilton (Vice President People …See details»
Site Map - Galera Therapeutics, Inc.
©2024 Galera Therapeutics, Inc. All Rights Reserved. Privacy Policy; Terms of Use; Site Map; Expanded Access PolicySee details»
Galera Therapeutics Appoints Linda B. West to Board of Directors
Apr 2, 2020 Galera is developing a second product candidate, GC4711, which successfully completed a Phase 1 trial in healthy volunteers. Galera is headquartered in Malvern, PA. For …See details»
Galera Therapeutics - Golden
Galera Therapeutics is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the …See details»
Patients & Caregivers - Galera Therapeutics, Inc.
Lung cancer is the leading cause of cancer death in the U.S., with approximately 238,000 cases diagnosed each year and more than 125,000 deaths. 1 Non-small cell lung cancer (NSCLC) is …See details»
Galera Reports Second Quarter 2022 Financial Results and Recent ...
Aug 9, 2022 For more information, please visit www.galeratx.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private …See details»
Galera Reports First Quarter 2023 Financial Results and Recent ...
©2024 Galera Therapeutics, Inc. All Rights Reserved. Privacy Policy; Terms of Use; Site Map; Expanded Access PolicySee details»
Privacy Policy - Galera Therapeutics, Inc.
You can always reach us online at legal@ null galeratx.com. You can reach us via mail at the address below. If you send us a letter, please provide your name, address, email address, and …See details»